Sernova (TSE:SVA) Price Target Cut to C$2.50 by Analysts at Ventum Financial

Sernova (TSE:SVA) had its price objective lowered by Ventum Financial from C$3.00 to C$2.50 in a report released on Friday morning, BayStreet.CA reports. The brokerage currently has a buy rating on the stock.

Separately, Leede Financial decreased their price target on Sernova from C$3.00 to C$1.50 and set a speculative buy rating for the company in a report on Friday.

Sernova Stock Performance

Shares of Sernova stock opened at C$0.26 on Friday. The stock has a market capitalization of C$82.72 million, a price-to-earnings ratio of -2.08 and a beta of 1.38. The firm’s fifty day simple moving average is C$0.27 and its 200-day simple moving average is C$0.38. The company has a debt-to-equity ratio of 16.55, a current ratio of 0.62 and a quick ratio of 18.11. Sernova has a 12 month low of C$0.20 and a 12 month high of C$0.83.

Sernova (TSE:SVA) last posted its quarterly earnings data on Friday, June 14th. The company reported C($0.03) earnings per share for the quarter, hitting analysts’ consensus estimates of C($0.03). As a group, equities analysts forecast that Sernova will post -0.08 earnings per share for the current year.

Insider Buying and Selling at Sernova

In related news, Director Steven Sangha sold 930,000 shares of Sernova stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of C$0.24, for a total value of C$223,200.00. In the last 90 days, insiders have acquired 359,600 shares of company stock valued at $92,771. 12.98% of the stock is owned by corporate insiders.

About Sernova

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection.